{"protocolSection":{"identificationModule":{"nctId":"NCT06481969","orgStudyIdInfo":{"id":"SF2024-2-40911"},"organization":{"fullName":"Peking University Third Hospital","class":"OTHER"},"briefTitle":"Application of Autologous Adipose Stromal Vascular Fraction in the Treatment of Premature Ovarian Insufficiency","officialTitle":"Application of Autologous Adipose Stromal Vascular Fraction in the Treatment of Premature Ovarian Insufficiency","acronym":"aSVF-POI"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-12-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-25","studyFirstSubmitQcDate":"2024-06-25","studyFirstPostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Rui Yang","investigatorTitle":"inofficious","investigatorAffiliation":"Peking University Third Hospital"},"leadSponsor":{"name":"Rui Yang","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A single-center, prospective, randomised controlled clinical trial (1:1 treatment ratio), designed to investigate the efficacy and safety of autologous SVF in improving the pregnancy outcome of infertile patients with POI.","detailedDescription":"A single-center, large-scale, prospective, randomized controlled clinical trial will enroll 260 patients diagnosed with POI based on the inclusion and exclusion criteria from Peking University Third Hospital. Eligible participants will be randomized to two groups at a ratio of 1:1- SVF protocol, and conventional protocol.The participation in this study will be approximately 2 years with a total of 6 visits and 3 follow-up phone calls."},"conditionsModule":{"conditions":["Premature Ovarian Insufficiency"],"keywords":["Female fertility","Premature Ovarian Insufficiency","Adipose stromal vascular fraction"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Eligible participants will be randomized to two groups at a ratio of 1:1- SVF protocol, and conventional protocol.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","maskingDescription":"Due to the particularity of the treatment plan, the evaluator, namely the follow-up personnel who collect the postoperative medical history and the ultrasound evaluator, will be blinded in this trial to hide the grouping results. Blinding of participants and researchers is not possible.","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":260,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Group A-SVF group","type":"EXPERIMENTAL","description":"Qualified participants will be randomized into either of two groups. Participants in this group will undergo lower abdominal liposuction, preparation of SVF and ovarian injection, other standard assisted reproductive treatments are similar and parallel between two groups.","interventionNames":["Procedure: Lower abdominal liposuction and preparation of SVF","Procedure: Ovarian injection"]},{"label":"Group B-Control group","type":"OTHER","description":"Qualified participants will be randomized into either of two groups. Participants in this group will be treated according to the current clinical routine of the reproductive center, other standard assisted reproductive treatments are similar and parallel between two groups.","interventionNames":["Procedure: Conventional IVF"]}],"interventions":[{"type":"PROCEDURE","name":"Conventional IVF","description":"Conventional In Vitro Fertilization (IVF) procedure and standard assisted reproductive treatments.","armGroupLabels":["Group B-Control group"]},{"type":"PROCEDURE","name":"Lower abdominal liposuction and preparation of SVF","description":"After lower abdominal liposuction (the liposuction volume is about 100 ml), the preparation and quality inspection of SVF will be completed by a laboratory with good manufacturing practice-approved facilities immediately. The adipose tissue will be cut into pieces of about 1mm3, and the equal volume of 0.1% collagenase I will be added to digest the adipose tissue. The digestion will be terminated after 40 minutes, followed by isolation, filtration, centrifugation, resuspension and dilution to obtain the SVF suspension. The test items, including bacteria, fungi, viruses and endotoxin, will be tested, and the expression of SVF surface markers, including CD45, CD34, CD31, CD11b, CD44, CD73, CD105 and CD90, will be detected by flow cytometry to ensure the quality of the SVF suspension. After about 4 hours of quality control and detection, the SVF suspension will be transported to the operating room on ice in a sealed incubator.","armGroupLabels":["Group A-SVF group"]},{"type":"PROCEDURE","name":"Ovarian injection","description":"Under ultrasound guidance, the SVF suspension will be injected into patients' bilateral ovaries. SVF with a total amount of (1\\~2)×107 cells from autologous fat tissue will be transplanted into each side of ovary. There are 3 injection points on each side of ovary, and 330±10μl SVF suspension will be administered at each point. The administration volume of each ovary will be 1ml in total. After injection, the patients will be required to lie flat for 2 hours to observe whether there would be adverse events.","armGroupLabels":["Group A-SVF group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The cumulative clinical pregnancy rate in half a year","description":"Percentage of patients with clinical pregnancy within half a year after treatment","timeFrame":"half a year after treatment"}],"secondaryOutcomes":[{"measure":"Serum level of Anti-Mullerian hormone (AMH)","description":"Efficacy rate (%) = The number of patients with two consecutive increases in serum level of AMH after treatment / total number of included patients×100%","timeFrame":"half a year after treatment"},{"measure":"Antral follicles count (AFC)","description":"Efficacy rate (%) = The number of patients with bilateral ovarian AFC increases by at least 2 after treatment / total number of included patients×100%","timeFrame":"half a year after treatment"},{"measure":"Serum level of sex hormone (E2 and FSH)","description":"Efficacy rate (%) = The number of patients with two consecutive increases/decreases in serum level of E2/FSH after treatment / total number of included patients×100%","timeFrame":"half a year after treatment"},{"measure":"Ovarian volume","description":"Ovarian volume will be recorded before and after treatment. Paired sample t-test or independent sample t-test will be used to compare the changes in ovarian volume between the control and SVF treatment groups, P \\< 0.05 will be recorded as significant change in ovarian volume.","timeFrame":"half a year after treatment"},{"measure":"Menstrual status","description":"The frequency, duration and volume of menses within half a year after treatment will be recorded to evaluate whether the menstrual status of patients have improved. Menstrual recovery rate (%) = The number of patients with menstrual recovery after treatment / total number of included patients × 100%.","timeFrame":"half a year after treatment"},{"measure":"Pregnancy outcome","description":"Live births or miscarriage of patients with successful pregnancy within half a year will be followed up. Live birth defined as the delivery of at least one viable fetus after 24 weeks gestation. Miscarriage defined as a loss of pregnancy before 24 weeks gestation. Live birth rate (%) = The number of patients with live births after treatment / total number of included patients×100%. Miscarriage rate (%) = The number of patients with miscarriage after treatment / total number of included patients×100%.","timeFrame":"2 years after treatment"},{"measure":"Health status of offspring","description":"The health status (survival, physiological and intellectual development) of offspring will be followed up via telephone for 2 years.","timeFrame":"2 years after treatment"},{"measure":"Adverse reactions","description":"The frequency, date of onset, duration and severity of any local and systemic adverse reactions will be observed and recorded during the entire follow-up period. Incidence rate of adverse reactions (%) = The number of patients with adverse reactions after treatment / total number of included patients×100%.","timeFrame":"2 years after treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Women aged ≥20 and ≤39 years who have childbearing requirements.\n* Cessation of menstruation or oligomenorrhea for at least 4 months\n* Serum level of basal follicle stimulating hormone (FSH) \\>25 U/L at least 2 times (during the second to fourth day of the menstrual cycle or during amenorrhea; The interval between the two tests is 4 weeks)\n* Serum level of Anti-Mullerian hormone (AMH) ≤1.1 ng/ml\n* Women with intact uterus and bilateral adnexa.\n* Voluntary participation and informed consent obtained.\n\nExclusion Criteria:\n\n* Women with autoimmune diseases.\n* Women with abnormal and uncontrolled thyroid function.\n* Women with tumors in bilateral adnexa that are not clearly benign or malignant.\n* Women with a history of malignant tumors, radiation therapy or chemotherapy.\n* Women with a history of venous thrombosis or pulmonary embolism during the screening period.\n* Women with severe illnesses that are not suitable for pregnancy, such as diseases of the circulatory system, urinary system, digestive system, endocrine system, respiratory system, immune system, mental or neurological system, etc.\n* Women who continuously used systemic glucocorticoids or other immunosuppressants for≥3 weeks within 6 months before administration and women who used systemic glucocorticoids (prednisone≥20 mg/d or equivalent dose) or other immunosuppressants within 3 days before administration.\n* Women who are allergic to the active ingredients or excipients of test drugs.\n* Women with a family history of severe genetic diseases or gynecologic malignancies.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"20 Years","maximumAge":"39 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Rui Yang, M.D.","role":"CONTACT","phone":"+86-010-82265080","email":"yrjeff@126.com"},{"name":"Yaodong Zhang, Bachelor","role":"CONTACT","email":"zyddoctor99@163.com"}],"overallOfficials":[{"name":"Rui Yang, M.D.","affiliation":"Peking University Third Hospital","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Peking University Third Hospital","status":"RECRUITING","city":"Beijing","state":"Beijing","zip":"100191","country":"China","contacts":[{"name":"Rui Yang, M.D.","role":"CONTACT","phone":"+86-010-82265080","email":"yrjeff@126.com"},{"name":"Yaodong Zhang, Bachelor","role":"CONTACT","email":"zyddoctor99@163.com"},{"name":"Xiumei Zhen, M.D.","role":"SUB_INVESTIGATOR"},{"name":"Jia Li, M.D.","role":"SUB_INVESTIGATOR"},{"name":"Hongsen Bi, M.D.","role":"SUB_INVESTIGATOR"},{"name":"Xiaojuan Liu, M.D.","role":"SUB_INVESTIGATOR"},{"name":"Tian Tian, M.D.","role":"SUB_INVESTIGATOR"},{"name":"Yanru Lou, Bachelor","role":"SUB_INVESTIGATOR"},{"name":"Chenhong Liu, Bachelor","role":"SUB_INVESTIGATOR"},{"name":"Jialin Li, Bachelor","role":"SUB_INVESTIGATOR"},{"name":"Lina Yi, Bachelor","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000047928","term":"Premature Birth"},{"id":"D000008594","term":"Menopause, Premature"},{"id":"D000016649","term":"Primary Ovarian Insufficiency"}],"ancestors":[{"id":"D000007752","term":"Obstetric Labor, Premature"},{"id":"D000007744","term":"Obstetric Labor Complications"},{"id":"D000011248","term":"Pregnancy Complications"},{"id":"D000005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D000010049","term":"Ovarian Diseases"},{"id":"D000000291","term":"Adnexal Diseases"},{"id":"D000005831","term":"Genital Diseases, Female"},{"id":"D000052776","term":"Female Urogenital Diseases"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D000006058","term":"Gonadal Disorders"},{"id":"D000004700","term":"Endocrine System Diseases"}],"browseLeaves":[{"id":"M25869","name":"Premature Birth","asFound":"Premature","relevance":"HIGH"},{"id":"M11577","name":"Menopause, Premature","asFound":"Premature Ovarian Insufficiency","relevance":"HIGH"},{"id":"M19020","name":"Primary Ovarian Insufficiency","asFound":"Premature Ovarian Insufficiency","relevance":"HIGH"},{"id":"M10772","name":"Obstetric Labor, Premature","relevance":"LOW"},{"id":"M10764","name":"Obstetric Labor Complications","relevance":"LOW"},{"id":"M14127","name":"Pregnancy Complications","relevance":"LOW"},{"id":"M2875","name":"Urogenital Diseases","relevance":"LOW"},{"id":"M27093","name":"Female Urogenital Diseases","relevance":"LOW"},{"id":"M8399","name":"Female Urogenital Diseases and Pregnancy Complications","relevance":"LOW"},{"id":"M12972","name":"Ovarian Diseases","relevance":"LOW"},{"id":"M3643","name":"Adnexal Diseases","relevance":"LOW"},{"id":"M8943","name":"Genital Diseases, Female","relevance":"LOW"},{"id":"M2876","name":"Genital Diseases","relevance":"LOW"},{"id":"M9163","name":"Gonadal Disorders","relevance":"LOW"},{"id":"M7862","name":"Endocrine System Diseases","relevance":"LOW"},{"id":"T6036","name":"Menopause","relevance":"LOW"}],"browseBranches":[{"abbrev":"BXS","name":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC19","name":"Gland and Hormone Related Diseases"}]}},"hasResults":false}